Market Overview:
The global intracranial hemorrhage therapeutics market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of intracranial hemorrhages, rising geriatric population, and technological advancements in the field of intracranial hemorrhage therapeutics. The global intracranial hemorrhage therapeutics market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into anti-hypertensive medicine, anti-anxiety medicine, hyperosmotic medicine, and anti-seizure medicine. On the basis of application, the market is segmented into hospitals, clinics,, and other segments. The hospitals segment dominates this market owing to increased awareness about early diagnosis and treatment for intracranial hemorrhages among patients visiting these healthcare facilities. Geographically,.the global Intracranian Hemorrhage Therapeutic Marketis dividedinto five regions: North America,.Latin America,.Europe., Asia Pacific.,and Middle East & Africa (MEA). In terms of revenue,.North America accounted forthe largest shareof 36%in 2017andis projectedto maintain its dominanceduringthe forecastperioddue toyourging demandfor better healthcare infrastructureand increasing prevalenceof neurological disordersin this region.
Product Definition:
Intracranial Hemorrhage Therapeutics is a therapy used to treat intracranial hemorrhage, a condition in which blood accumulates in the brain. Intracranial hemorrhage can result from various causes, including head injuries, stroke, and cerebral aneurysm rupture. Treatment for intracranial hemorrhage may include medications such as blood thinners and corticosteroids to reduce inflammation, and surgery to remove the blood clot.
Anti-hypertensive Medicine:
Anti-hypertensive medicines are the drugs that help to lower the blood pressure. Blood pressure is a measure of how hard blood pushes against the arteries when oxygenated by the heart. High blood pressure (hypertension) can damage many parts of the body such as kidneys, brain, and heart. It also increases risks for stroke and coronary artery disease.
Anti-anxiety Medicine:
Anti-anxiety medicine is used to treat the symptoms of anxiety. It works by enhancing the action of natural chemicals in the brain, which reduce anxiety. The most commonly prescribed anti-anxiety medicines are benzodiazepines such as Valium and Ativan, selective serotonin reuptake inhibitors (SSRIs) such as Zoloft and Paxil, and anticonvulsants such as Carbamazepine (Tegretol).
Application Insights:
Based on application, the global intracranial hemorrhage therapeutics market is segmented into hospitals, clinics and other. Hospitals held the largest share in 2017 owing to factors such as a large patient base and high prevalence of co-morbidities. Furthermore, hospital based settings offer advanced monitoring facilities along with highly skilled personnel which boosts overall revenue generation in this segment.
Clinics are expected to witness lucrative growth over the forecast period due to increasing awareness about ICH care among physicians as well as patients suffering from TBIs across the globe. Moreover, an increase in number of TBI related deaths has led clinicians worldwide towards developing better treatment options for such patients which eventually benefits market growth over forecast period. Other emerging segments include dedicated ICH clinics and mobile intensive care units (mICUs).
Regional Analysis:
Asia Pacific dominated the global market in 2017. This can be attributed to increasing prevalence of hypertension, rising awareness about ICH care, and growing healthcare expenditure. According to WHO data, approximately 60% of the population in China suffers from hypertension; however, only 30% have been diagnosed with it. Thus, a large number of patients are suffering from high blood pressure but remain untreated due to lack of awareness and access to treatment in rural areas as well as urban centers.
In addition an estimated 90 million people suffer from panic disorder (PD) globally; however only 40 million receive treatment for their condition each year owing to its stigma attached with it which makes individuals reluctant towards seeking help for PD or other associated disorders such as anxiety or agoraphobia.
Growth Factors:
- Increasing incidence of intracranial hemorrhage
- Growing awareness about intracranial hemorrhage and its treatment options
- Rising demand for better and safer treatments for intracranial hemorrhage
- Technological advancements in the field of intracranial hemorrhage treatment
- increasing funding for research and development in the field of intracranian hemorrhages
Scope Of The Report
Report Attributes
Report Details
Report Title
Intracranial Hemorrhage Therapeutics Market Research Report
By Type
Anti-hypertensive Medicine, Anti-anxiety Medicine, Hyperosmotic Medicine, Anti-seizure Medicine
By Application
Hospitals, Clinics, Other
By Companies
Bayer, Boehringer Ingelheim, Johnson and Johnson, Novo Nordisk, Bristol-Myers Squibb, H. Lundbeck, Oxurion, Ligand Pharmaceuticals, Neurotec Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
162
Number of Tables & Figures
114
Customization Available
Yes, the report can be customized as per your need.
Global Intracranial Hemorrhage Therapeutics Market Report Segments:
The global Intracranial Hemorrhage Therapeutics market is segmented on the basis of:
Types
Anti-hypertensive Medicine, Anti-anxiety Medicine, Hyperosmotic Medicine, Anti-seizure Medicine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Boehringer Ingelheim
- Johnson and Johnson
- Novo Nordisk
- Bristol-Myers Squibb
- H. Lundbeck
- Oxurion
- Ligand Pharmaceuticals
- Neurotec Pharma
Highlights of The Intracranial Hemorrhage Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-hypertensive Medicine
- Anti-anxiety Medicine
- Hyperosmotic Medicine
- Anti-seizure Medicine
- By Application:
- Hospitals
- Clinics
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Intracranial Hemorrhage Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Intracranial hemorrhage therapies are medications and treatments used to prevent or treat an intracranial hemorrhage. These therapies may include blood thinners, clotting agents, and other medications.
Some of the major players in the intracranial hemorrhage therapeutics market are Bayer, Boehringer Ingelheim, Johnson and Johnson, Novo Nordisk, Bristol-Myers Squibb, H. Lundbeck, Oxurion, Ligand Pharmaceuticals, Neurotec Pharma.
The intracranial hemorrhage therapeutics market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Intracranial Hemorrhage Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Intracranial Hemorrhage Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Intracranial Hemorrhage Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Intracranial Hemorrhage Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Intracranial Hemorrhage Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Intracranial Hemorrhage Therapeutics Market Size and Y-o-Y Growth
4.5.2 Intracranial Hemorrhage Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Intracranial Hemorrhage Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Intracranial Hemorrhage Therapeutics Market Size Forecast by Type
5.2.1 Anti-hypertensive Medicine
5.2.2 Anti-anxiety Medicine
5.2.3 Hyperosmotic Medicine
5.2.4 Anti-seizure Medicine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Intracranial Hemorrhage Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Intracranial Hemorrhage Therapeutics Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Intracranial Hemorrhage Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Intracranial Hemorrhage Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Intracranial Hemorrhage Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Intracranial Hemorrhage Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Intracranial Hemorrhage Therapeutics Market Size Forecast by Type
9.6.1 Anti-hypertensive Medicine
9.6.2 Anti-anxiety Medicine
9.6.3 Hyperosmotic Medicine
9.6.4 Anti-seizure Medicine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Intracranial Hemorrhage Therapeutics Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Intracranial Hemorrhage Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Intracranial Hemorrhage Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Intracranial Hemorrhage Therapeutics Market Size Forecast by Type
10.6.1 Anti-hypertensive Medicine
10.6.2 Anti-anxiety Medicine
10.6.3 Hyperosmotic Medicine
10.6.4 Anti-seizure Medicine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Intracranial Hemorrhage Therapeutics Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Intracranial Hemorrhage Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Intracranial Hemorrhage Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Intracranial Hemorrhage Therapeutics Market Size Forecast by Type
11.6.1 Anti-hypertensive Medicine
11.6.2 Anti-anxiety Medicine
11.6.3 Hyperosmotic Medicine
11.6.4 Anti-seizure Medicine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Intracranial Hemorrhage Therapeutics Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Intracranial Hemorrhage Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Intracranial Hemorrhage Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Intracranial Hemorrhage Therapeutics Market Size Forecast by Type
12.6.1 Anti-hypertensive Medicine
12.6.2 Anti-anxiety Medicine
12.6.3 Hyperosmotic Medicine
12.6.4 Anti-seizure Medicine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Intracranial Hemorrhage Therapeutics Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Intracranial Hemorrhage Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Intracranial Hemorrhage Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Intracranial Hemorrhage Therapeutics Market Size Forecast by Type
13.6.1 Anti-hypertensive Medicine
13.6.2 Anti-anxiety Medicine
13.6.3 Hyperosmotic Medicine
13.6.4 Anti-seizure Medicine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Intracranial Hemorrhage Therapeutics Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Intracranial Hemorrhage Therapeutics Market: Competitive Dashboard
14.2 Global Intracranial Hemorrhage Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 Boehringer Ingelheim
14.3.3 Johnson and Johnson
14.3.4 Novo Nordisk
14.3.5 Bristol-Myers Squibb
14.3.6 H. Lundbeck
14.3.7 Oxurion
14.3.8 Ligand Pharmaceuticals
14.3.9 Neurotec Pharma
